All In Biotech

Drug Trial Radar · NCT07799532

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury

A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Trial (RESTORE)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Jul 2027

Study completion Dec 14, 2027

Sponsor

Lead sponsor
NervGen PharmaIndustry
Sponsor type
Industry
First posted
Sep 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and daily activities? * What side effects do participants have when taking NVG-291? Researchers will compare NVG-291 to a placebo (a look-alike substance that does not contain NVG-291) to see if NVG-291 improves function in adults with chronic cervical motor-incomplete spinal cord injury. Participants will: * Take NVG-291 or a placebo by injection under the skin (subcutaneous) once daily for 12 weeks. * Attend clinic visits for checkups and safety tests. * Complete tests and questionnaires about hand function, walking, daily activities, and quality of life. * Take part in an interview about changes in their condition, within 14 days after the Week 12 visit.

Conditions

  • Chronic Spinal Cord Injury

Interventions

  • NVG-291Drug

    NVG-291 is an investigational peptide therapeutic administered by subcutaneous injection. Participants randomized to the experimental arm will receive NVG-291 once daily for 12 weeks. NVG-291 is designed to promote nervous system repair and functional recovery following chronic spinal cord injury.

  • PlaceboDrug

    Matching placebo is supplied as a sterile lyophilized formulation matching NVG-291 in appearance and route of administration. Participants randomized to the placebo arm will receive placebo once daily by subcutaneous injection for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of NVG-291 as measured by change from baseline in combined Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Quantitative Prehension (QtP) scoreTime frame: Baseline to Week 12

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • NervGen NVG-291-301 Site#104

    Birmingham, Alabama · Not yet recruiting

  • NervGen NVG-291-301 Site# 118

    Pheonix, Arizona · Not yet recruiting

  • NervGen NVG-291-301 Site#109

    Downey, California · Not yet recruiting

  • Craig Hospital

    Englewood, Colorado · Recruiting

  • New England Institue for Clinical Research

    Stamford, Connecticut · Recruiting

  • NervGen NVG-291-301 Site#112

    Washington D.C., District of Columbia · Not yet recruiting

  • NervGen NVG-291-301 Site#107

    Miami, Florida · Not yet recruiting

  • Shepherd Center

    Atlanta, Georgia · Recruiting

  • International Neurorehabilitation Institute

    Lutherville, Maryland · Recruiting

  • NervGen NVG-291-301 Site # 121

    Boston, Massachusetts · Not yet recruiting

  • NervGen NVG-291-301 Site#111

    Rochester, Minnesota · Not yet recruiting

  • NervGen NVG-291-301 Site#115

    Camden, New Jersey · Not yet recruiting

  • NervGen NVG-291-301 Site#117

    Paramus, New Jersey · Not yet recruiting

  • NervGen NVG-291-301 Site#114

    West Orange, New Jersey · Not yet recruiting

  • NervGen NVG-291-301 Site#108

    Charlotte, North Carolina · Not yet recruiting

  • NervGen NVG-291-301 Site# 119

    Cleveland, Ohio · Not yet recruiting

  • NervGen NVG-291-301 Site#116

    Philadelphia, Pennsylvania · Not yet recruiting

  • NervGen NVG-291-301 Site#113

    Charleston, South Carolina · Not yet recruiting

  • NervGen NVG-291-301 Site#110

    Houston, Texas · Not yet recruiting

  • NervGen NVG-291-301 Site# 120

    Richmond, Virginia · Not yet recruiting

  • NervGen NVG-291-301 Site#102

    Milwaukee, Wisconsin · Not yet recruiting

  • NervGen NVG-291-301 Site# 202

    Edmonton, Albert, Canada · Not yet recruiting

  • NervGen NVG-291-301 Site#201

    Vancouver, British Columbia, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.